(22S)-Budesonide
CAS: 51372-28-2
Ref. 3D-FB19348
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
- (11b,16a)-16,17-[(1S)-Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
- (11β,16α)-16,17-[(1S)-Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
- (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
- Budesonide (11beta,16alpha(S))
- Pregna-1,4-diene-3,20-dione, 16,17-[(1S)-butylidenebis(oxy)]-11,21-dihydroxy-, (11β,16α)-
- Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, [11β,16α(S)]-
- Unii-168L5Ht37P
(22S)-Budesonide is a glucocorticoid that has anti-inflammatory activity. It is used to treat asthma, chronic cough, and bowel disease. It is also used to reduce the inflammation in diseases such as rheumatoid arthritis and ulcerative colitis. (22S)-Budesonide is a prodrug that is metabolized into its active form by hydrolysis of the ester bond by esterases or glucuronidases. The active drug then binds to glucocorticoid receptors on cells in the body and suppresses the immune system. (22S)-Budesonide has been shown to have an effect on bacterial rhinosinusitis, with prolonged treatment leading to a reduction in disease activity. This drug also reduces cortisol concentrations in patients with Crohn's disease, which may be due to its ability to bind to basic proteins such as albumin or immunoglobulins.
